What caused the AYA.AX stock fall on 16 Mar 2026?

AYA.AX stock fell after weak intraday momentum and volume below the 50‑day average; traders reacted to continued negative EPS and mixed technical indicators, while waiting for adoption and reimbursement catalysts.

What is Meyka AI's forecast for AYA.AX stock?

Meyka AI's forecast model projects monthly **A$3.05**, quarterly **A$4.36**, and yearly **A$7.41** for AYA.AX stock; these are model projections and not guarantees.

Is AYA.AX stock a buy for growth investors?

AYA.AX stock is a growth‑stage healthcare AI play with adoption upside but negative earnings and high R&D; Meyka AI grades it B (HOLD), so weigh clinical adoption milestones before increasing exposure.

Where can I read more company details and comparisons?

Company profile and recent overview are available on StockAnalysis and sector comparisons can be found on Investing.com for ASX healthcare peers. See sources below.

AU Stocks

AYA.AX Artrya ASX down 7.42% to A$3.12 16 Mar 2026: AI diagnostics outlook

ByHuzaifa Zahoor March 16, 2026March 16, 2026

AYA.AX stock fell 7.42% to A$3.12 on 16 Mar 2026 as traders reacted to weak near-term momentum in AI-enabled imaging sales. The move closed the ASX session after a day range of A$3.06–A$3.22 and volume of 138,476 shares, below the 50‑day average of A$3.67. Investors should weigh Artrya Limited’s Salix adoption and long-term AI opportunity in coronary diagnostics against current losses and negative EPS of -0.17.